Check out our latest industry white papers. Browse now!
Sales & Support: +1 800 762 3361
Member Resources

Indian pharmaceuticals major, Cipla Limited, has received approval from the Drug Controller General of India (DCGI) to conduct clinical trials of the influenza drug Favipiravir to examine its efficacy in treating COVID-19. After acquiring the drug production process from the state-run Indian Institute of Chemical Technology (IICT), Cipla sought approval from Indian regulators to launch the experimental drug. IICT has developed a cost-effective synthetic process for producing Favipiravir, which was originally produced by Fujifilm Toyama Chemical Limited in Japan for treatment of common influenza.

Login or Register for Instant Access

Subscribe Now!

(All Fields Required)

IIR Logo Globe

Site-wide Scheduled Maintenance for April 12, 2025, between 9 A.M. - 9 P.M. CST. During this time, all services will be unavailable periodically throughout the scheduled maintenance window.

×
×

Contact Us

For More Info!